Europe Market Readiness Clarity system and assays are CE-marked and commercially available in Europe, with a 510(k) submission to the U.S. FDA historically filed. This creates a clear expansion channel to European hospitals, reference laboratories, and distributors, with opportunities for regional partnerships, co-marketing, and localized service offerings to accelerate adoption of ultra-sensitive immunodiagnostics.

Ultra-Sensitive Edge Single Molecule Counting provides up to 1000x higher sensitivity for biomarker measurement, enabling precise detection for precision medicine and companion diagnostics. This differentiator supports partnerships with pharma/biotech and existing collaborators to integrate ultra-sensitive assays into diagnostic workflows.

Strategic Collaborations A proven track record with Qiagen, Grifols, and academic partners signals a viable path for business development through co-development and co-commercialization. Target channels include pharma, contract research organizations, and academic centers to broaden adoption and establish reference customers.

Infectious Disease Growth The CDI toxin assay launch demonstrates capability in infectious disease diagnostics, with additional infectious and inflammatory assays in development. This creates opportunities for pilots and early-adopter labs, hospitals, and regional distributors seeking high-sensitivity tests.

Nonclinical and POC The move toward a point-of-care platform and exploration of non-clinical applications opens paths to research laboratories, environmental testing, and industrial biotech markets. Potential sales avenues include licensing, co-development, or distributor partnerships to broaden the footprint beyond traditional in vitro diagnostics.